Since entering the immunological stage several decades ago, regulatory T cell biology has been realized as fundamentally important in the prevention of autoimmune conditions, induction of transplant tolerance and the immune response to cancer. The role of regulatory T cells in tumor immunobiology is still being elucidated. Currently, regulatory T cells are implicated in the dampening of antitumor T-cell responses both through direct and indirect means. A number of investigators have demonstrated that regulatory T cell density and location may serve as independent prognostic factors in several types of cancer and are alternately detrimental or beneficial to patient survival. In this article, we will review the characteristics and functional phenotype of classical regulatory T cells, describe their distribution and quantification in tumor-bearing hosts and summarize recent studies investigating the prognostic significance of regulatory T cell number and locality in various cancers.
Regulatory T (T Reg ) cells are a subpopulation of CD4
þ T cells with suppressive functionality. In healthy individuals, perhaps the most important role of regulatory T cells is to maintain immune tolerance to self-antigens, which prevents development of autoimmune disease. T Reg cells are also responsible for limiting tissue damage during ongoing and resolving immune responses, maintaining oral and fetomaternal tolerance and restraining asthma and allergy. In settings of organ transplant and cancer, the suppressive function of T Reg cells is currently being manipulated to improve patient health and survival. Investigators of transplantation biology are exploring ways to increase the number of alloantigen-reactive regulatory T cells in transplant recipients to minimize grafted tissue damage and prevent organ rejection. 1 In cancer patients, where regulatory T cells contribute to the dampening of the antitumor immune response, combination therapies that include the inhibition of regulatory T cell function have been explored. Although few Stage III trials of T Reg inhibition have reached their clinical endpoints, analysis of T Reg cells in tumor environments can still yield useful information about patient prognosis and tumor growth, and may eventually lead to new, more successful treatment regimes.
Definition
Regulatory T cells, originally termed suppressive T cells, were first described by Gershon et al. 2, 3 in the early 1970s as thymus-derived lymphocytes that tolerized bone marrowderived lymphocytes to antigenic challenge. Research in the laboratory of R.J. North subsequently demonstrated that T cells expressing CD4 and CD25 from tumor-bearing mice abrogated tumor rejection; this suggested the existence of a tumor-suppressor T cell population [4] [5] [6] . Many years later, after more than a decade of intense skepticism regarding the suppressive cells' existence, Sakaguchi et al. ascertained that the interleukin-2 (IL-2) receptor a-chain (also called CD25) could be used to identify them. 7 Later studies in the same laboratory, as well as studies from Rudensky et al., established the transcription factor forkhead box P3 (FoxP3) as both a key intracellular marker of CD4þ CD25þ regulatory T cells and necessary factor for development and proper function of these cells, [8] [9] [10] which was described early on as prevention of autoimmune conditions (e.g., colitis 11 ) and suppression of CD8þ T cell homeostatic proliferation. 12 Beginning with these reports, the field of regulatory T cells has expanded and progressed rapidly. In fact, several distinct regulatory T cell populations have been proposed, including CD8þ subsets. These include thymically derived CD8þ CD25þ T cells that utilize cytotoxic T-lymphocyte-associated antigen-4 (CTLA4) and transforming growth factor b (TGFb) to suppress cell proliferation and activation, 13 as well as a CD8þ CD28À T cell population from the periphery that targets immunoglobulin-like transcripts 3 (ILT3) and 4 (ILT4) on dendritic cells (DCs). 14 Our group has identified CD8þ T cells 15, 16 in human ovarian cancer that secrete the suppressive cytokine interleukin-10 (IL-10). Interestingly, a CD8þ regulatory T cell population specific for heme oxygenase-1 has recently been identified. 17 This population, isolated from the peripheral blood of cancer patients, inhibited proliferation, cytotoxicity and cytokine production of other cell immune cells. Groux et al. identified a FoxP3-CD4þ population (termed T R 1 cells), which may also suppress through IL-10 in vitro. population (T H 3) that exerts suppressive action in vivo through TGFb. 19 Both aforementioned populations are likely derived from the periphery. Classic regulatory T cells (T Reg ), CD4þCD25þFoxP3þ T cells, differentiate in the thymus and migrate to the periphery. 20, 21 They constitutively express leukocyte common antigen isoform RO (CD45RO), glucocorticoid-induced tumor-necrosis factor receptor-related protein (GITR) and CTLA-4. [22] [23] [24] [25] [26] Fascinatingly, research from Arne Akbar's group has demonstrated that functional T Reg may be induced from memory CD4þ T cell populations found in inflamed skin. 27 These antigen-specific CD4þ T cells were isolated, rendered anergic and then tested for suppressive capacity. Interestingly, in parallel with their newly acquired suppressive ability, FoxP3þ mRNA and protein expression in these cells increased profoundly, while CD25, GITR and CTLA-4 expression were all up-regulated. Finally, a recent paper from the laboratory of Shimon Sakaguchi presents the possibility of further categorizing naturally occurring T Regs into three subgroups: CD45RAþ FoxP3 lo resting T Reg , termed ''rTreg'' by the authors, CD45RAÀ FoxP3 hi activated Treg (aTreg) cells and cytokine-secreting CD45RA-FoxP3 lo nonsuppressive T cells. 28 Ongoing investigations into phenotype, function and associations with disease states will likely contribute to knowledge of an even wider range of regulatory T cell populations in the future. Regardless, it is important to emphasize that regulatory T cells must be defined not only by phenotypic markers but also by their suppressive activity in vivo.
Distribution in Tumor-Bearing Hosts
In healthy mice and humans, T Reg cells are found primarily in the thymus, peripheral blood, lymph nodes and spleen. They constitute 5-10% of the resident CD4þ T cells in each of these organs. [29] [30] [31] In bone marrow, however, T Reg cells account for a remarkable 25% of CD4þ T cells. 32 Bone marrow is the preferential site of metastasis for some cancers (such as breast, lung and prostate), suggesting that the suppressive environment here is conducive to tumor growth. In tumors themselves, however, there are a number of ways that T Reg cells might accumulate: trafficking to the tumor under the influence of chemokine ligand 22 (CCL22), 33 differentiation 15, 16, [34] [35] [36] [37] or expansion [38] [39] [40] within the tumor stroma and conversion from normal T cells. [41] [42] [43] [44] Many tumors express tumor-associated antigens (TAAs), molecules found not only on tumor cells but also on certain populations of normal cells. The work of several groups has identified multiple mechanisms of suppression by TAA-specific T Reg cells. These include induction of IL-10, which can drastically suppress antigen-presenting cell (APC) and T cell function, 45 induction of TGFb, which may suppress natural killer (NK) cell function, 46 competitive consumption of interleukin-2 (IL-2), which is a survival factor for conventional T cells, 29, 47, 48 perforin-and granzyme-dependent killing of T cells and APCs, 49, 50 CTLA-4 induction of indolamine 2,3-dioxygenase (IDO)-expressing APCs, which suppress T cell activation and promote tolerance, 51, 52 and finally, induction of B7-H4 expression on APCs, which renders them immunosuppressive. 53, 54 Thus, T Reg cells target both T cells and APCs to create a generally tolerant tumor microenvironment.
Mouse tumors
Tumor-associated T Reg cells have been studied largely with reagents that target T Reg cells in tumor-bearing mice. Treatment with CD25-specific antibody (PC61) in vivo suppressed growth of several tumor types. 55, 56 These early studies demonstrated a correlation between reduced T Reg numbers and reduced tumor volume. Interestingly, depletion of total CD4þ T cells corroborated these data and lead to improved tumor immunity and rejection of tumors. [57] [58] [59] Several groups confirmed these data with CD25-depletion alone or in concert with other treatments, such as anti-CTLA4 antibody, 58 anti-B7H1 antibodies (Zou et al., unpublished observations), exogenous interferon-a (IFNa) 60 or interleukin-12 (IL-12), 61 adoptive transfer of DCs 60, 62 and irradiated tumor cells. 63 Adoptive transfer of human 33 or mouse 64, 65 T reg cells into mice have also provided a direct functional connection between T Reg cell presence and reduced tumor immunity. One study examined B16 melanoma-bearing mice that received tumor-specific CD8þ T cells with either classic T Reg cells or with CD25À CD4þ T cells.
65 CD8þ T-cell-mediated tumor immunity was abrogated in mice receiving classic T Reg cells, but not CD25À CD4þ T cells. These studies demonstrate that T Reg cells inhibit murine TAA-specific immunity.
Human tumors
June et al. observed increased numbers of T Reg cells in patients with nonsmall cell lung cancer and ovarian carcinoma when compared to healthy patients. 66 Since this study in 2001, several other groups have made similar observations in the peripheral blood of patients with various types of cancer, including pancreatic and breast cancer, 67 colorectal cancer (CRC), 68 
Quantification of Regulatory T Cells in Tumor
Regulatory T cell numbers may be evaluated in the tumor and tumor microenvironment in multiple ways. It is common for these cells to be identified on the basis of CD25 and/or FoxP3 expression. Quantification may be presented as a percentage of CD4þ T cells or total (CD3þ) T cells, or as absolute number per area (such as mm 3 ) in a given tissue, as in the recent study by Haas et al. 77 Additionally, data may take the form of the ratio of regulatory T cells: effector T cells. Typically, tissue samples are investigated either by creating tissue microarrays and using immunohistochemistry or processing the tissue and examining cell populations via flow cytometry. Importantly, it is known that cell types other than T Reg cells express what were formerly thought of as unique T Reg markers: both CD25 and FoxP3 can be expressed on activated T cells. [78] [79] [80] A recent publication has suggested that analysis of DNA methylation of the FoxP3þ gene may be a more conclusive way to identify T Reg cells 81 : apparently, a certain region within the FoxP3 gene (TSDR, T Reg -specific demethylated region) is demethylated. Because this demethylation is not found in other cell types-including those known to express FoxP3, like activated T cells-it allows for enumeration of T Regs via DNA quantification methods such as PCR. When presenting T Reg quantification data, it is important to consider it in the context of the numbers and locations of other lymphocytes associated with cancer prognoses, such as T-helper-17 (Th17) cells, tumor-associated macrophages (TAMs), and other APCs, especially DCs.
Association with Pathological and Clinical Outcome
Thus far, we have reviewed the current data on regulatory T cell phenotype, quantification and function in the tumor microenvironment. Much of the data suggests that a higher T Reg cell number within the tumor microenvironment would imply a worse prognosis. In many cases, this is true. However, regulatory T cell infiltration in and around the tumor can be beneficial, depending on the type of tumor in question.
Ovarian cancer
A study in 2003 by Zhang et al. found significant differences in the distributions of progression-free survival and 5-year overall survival (OS) of 186 epithelial ovarian cancer patients according to the presence or absence of intratumoral CD3þ T cells. 82 Intratumoral T cells correlated with delayed recurrence or death of patients. T cell presence was additionally associated with microenvironmental expression of lymphocyte-attracting chemokines and increased intratumoral levels of IL-2 and IFNc. While this study did not specifically address the presence or prognostic significance of T Reg cells, it supports the notion that T cell presence within the tumor is beneficial-the logical hypothesis, then, would be that suppression of intratumoral T cell activation might decrease survival. A subsequent study from the laboratory of Kunle Odunsi demonstrated that epithelial ovarian cancer patients with higher numbers of intraepithelial CD8þ T cells had improved survival (55 versus 26 months) compared with patients with lower numbers. 83 Interestingly, no survival association was found for CD3þ tumor infiltrating lymphocytes (TILs). However, the patients with high versus low intraepithelial CD8þ/CD4þ TIL ratios had median survival of 74 and 25 months, indicating that CD4þ TIL (or subpopulations thereof) might negatively influence the actions of CD8þ TIL. With this in mind, the investigators examined the survival of patients based upon intratumoral CD8þ/T Reg ratios. They found that patients with high ratios lived more than two times longer than those with lower ratios (58 vs. 23 months), and the study concluded that T Reg presence in tumor tissue can negatively impact patient prognosis. Our group published a study in 2004 in which we examined 104 patients with ovarian carcinoma. 33 In these patients, we
found that human tumor T Reg cells suppressed tumor-specific T cell immunity and contributed to tumor growth in vivo. T Reg cells were not only more populous in ascites and tumors of patients with Stage III and Stage IV disease, but were also associated with a strikingly high death hazard and reduced survival-patients with 341 or more T Reg cells per ten highpower fields (HPF) had a 25-fold higher risk of death than patients with 131 or fewer T Reg cells in the same number of fields. It is important to note that both tumor cells and TAMs produced the chemokine CCL22, which mediated T Reg recruitment to the tumor. In 2007, we published a report describing the relationship between B7-H4, T Reg cells, and the survival of 103 patients with ovarian cancer. 84 We had previously showed that ovarian tumor cells and TAMs expressed B7-H4. 53 Our data demonstrated that B7-H4 expression in tumor microenvironmental macrophages was significantly correlated with intratumoral T Reg numbers, and that both of these variables were associated with poor patient outcome. Tumor T Reg cells enabled local macrophages to spontaneously produce IL-10 and IL-6, through which the macrophages stimulated their own B7-H4 expression. Along with the 2004 study 33 and our more recent work demonstrating that T Reg cells induce B7-H4 on APCs (including macrophages), 54 our data support the notion that T Reg cells may convey suppressive activity to APCs through B7-H4 induction in human ovarian cancer. These four studies present a rather convincing picture that increased T Reg cell presence and function in ovarian cancer correlates with reduced survival. The data detailing involvement of other cell types in T Reg cell recruitment and function in the tumor emphasizes the necessity to comprehensively evaluate the cellular network in the tumor microenvironment.
Gastric cancer
Kawaida et al. published a study in 2005 documenting an increased number of CD4þ CD25 hi T cells in regional lymph nodes in gastric cancer patients when compared to control mesenteric lymph nodes from the same patients. 85 Functional tests of these cells confirmed inhibitory activity corresponding to T Reg cells. A subsequent report by Kono et al. investigated the proportion of CD4þ CD25hi FoxP3 mRNAexpressing T cells in total PBMC CD4þ T cells in 72 patients with gastric cancer and 42 patients with esophageal cancer. 86 Although they did not provide concrete numbers in the text of the study, the authors state that there were significant differences in the prevalence of CD4þCD25hi T cells between the early and advanced disease stages, both in gastric cancer ($2% in stage I vs. $7% in stage IV) and esophageal cancer (about 2.5% in stage I vs. $8% in stage IV). They also state that in both cancers, the patients with a high proportion of CD4þ CD25hi T cells showed poorer survival rates (about 40 vs. 93% after 6 years for gastric cancer, and 25 vs. 55% in esophageal cancer) in comparison to those with a low proportion. This study utilized small groups and was not specific about grouping parameters. 88 As might be expected, the frequency of T Reg cells in TILs was significantly higher than in normal gastric mucosa (12.4 vs. 4.1%) both in early and late disease. Interestingly, the frequency of CCL17þ or CCL22þ cells among intratumoral CD14þ cells (monocytes and macrophages) was significantly higher than that of normal gastric mucosa, and this frequency correlated significantly with tumor-infiltrating T Reg numbers. The investigators confirmed in an in vitro migration assay that T Reg cells could be induced to migrate by CCL17 or CCL22. This study supports the notion suggested previously by our group 33 that chemokines secreted by monocytes and macrophages within the tumor environment are important for T Reg trafficking into the tumor. More recently, Haas et al. published an investigation of T Reg prognostic significance in 52 patients with intestinal-type gastric cardiac cancer. 77 Although the group found no relationship between the numbers of T Reg cells (or macrophages) infiltrating the tumor and patient survival, they did observe that patients with larger T Reg populations in the tumor stroma (>125.9 FoxP3þTILs/mm 2 ) had a median survival time of 58 months while those with smaller populations (<125.9 FoxP3þTILs per mm 2 of tissue) had a median survival time of 32 months. Interestingly, they also discovered that patients with higher (above 2.9) stromal CD68þ (a glycoprotein expressed on monocytes and macrophages)/FoxP3þ cell ratios in primary tumor had shorter median survival time than those with lower ratios. This data again supports the concept of an immunosuppressive and/or tumor-promoting role for APC in the tumor microenvironment. Haas et al.
propose that their findings suggest that inflammatory processes within the tumor stroma of gastric cardiac adenocarcinomas may have direct effects on patient outcome. In opposition to the probable protumor role for macrophages, it is feasible that large numbers of stromal T Reg may inhibit local cancer-promoting inflammatory processes. Therefore, it is possible in patients with chronic inflammation-associated cancers such as gastritis-associated gastric adenocarcinoma and ulcerative colitis-associated colon cancer (see discussion below), T Reg may be protective.
Pancreatic cancer
In 2006, Hiraoka et al. performed a study of the clinical significance of T Reg in the progression of pancreatic ductal adenocarcinoma. 89 On investigation of tumor tissue and draining lymph nodes of 198 pancreatic ductal adenocarcinomas, their associated premalignant lesions and 15 non-neoplastic pancreatic lesions, the investigators found an increased T Reg prevalence in the ductal adenocarcinomas compared with that in the stroma of non-neoplastic lesions. This increase significantly correlated with certain clinicopathologic factors, including distant metastasis, advanced tumor stage and higher tumor grade. Interestingly, the investigators documented that infiltration of intraepithelial CD8þ cytotoxic T cells into pancreatic ducts was prominent in low-grade premalignant lesions but diminished during the progression of both pancreatic intraepithelial neoplasias and intraductal papillary-mucinous neoplasms. Conversely, numbers of stromal T Reg cells increased during this progression. Patients with a low frequency (less than the average 34.6% of total intratumoral CD4þ T cells) of tumor-infiltrating T Reg cells had significantly longer survival than those who had a high frequency (more than the average 34.6%) of intratumoral T Reg cells.
Anal cancer
A study by Grabenbauer et al. explored the prognostic significance of T Reg cells and TIL subsets in 38 anal squamous cell carcinoma patients treated with radiochemotherapy. 90 Although they found no prognostic effects for T Reg or macrophages, the investigators did determine that higher numbers of cytotoxic TIL numbers (>0.6 granzyme Bþ TILs per 100 tumor cells) served as indicators of poor prognosis (3-year survival rate of 47 vs. 89% in patients with fewer than 0.6 granzyme Bþ TIL per 100 tumor cells). Additionally, 3-year survival rates for patients with low numbers of TILs (defined as 3.8 CD3þ per 100 tumor cells or 1.5 CD4þ per 100 tumor cells) were 89 and 95%, respectively, and 54 and 48%, respectively, in cases with high numbers (>3.8 CD3þ per 100 tumor cells or >1.5 CD4þ per 100 tumor cells). It appears here that lower numbers of TILs indicate better patient outcome. However, the prognostic significance of these cell populations must be considered in light of the fact that the patients examined had already been treated with radiochemotherapy, and it is therefore possible that the Special Section Paper remaining tumor cells may have arisen from radiation-resistant precursors.
Colorectal cancer
A recent study by Salama et al. assessed the survival correlations of CD8þ, CD45ROþ and FoxP3þ T cell frequencies in tumor and normal colonic tissue from 967 patients with Stage II or Stage III CRC. 91 The investigators found that CD8þ and CD45ROþ cell densities (cells per mm 2 ) were lower in tumor than in normal tissue, but FoxP3þ cell density was higher. On comparison with normal colon tissue from the same patients, the investigators determined that densities of both T Reg and CD3þ T cell populations were increased in tumor tissue. Although intraepithelial FoxP3þ cell numbers were not prognostic, higher levels of expression were found to correlate with poor tumor differentiation, advanced patient age and, interestingly, female gender. As for CD3þ T cells, patients with smaller intraepithelial populations experienced reduced disease-free survival (DFS). A low intraepithelial CD3þ/FoxP3þ ratio (lower than the first quartile value of all patients) also served as a prognostic indicator for reduced DFS. Both of these variables were found to be prognostically stronger for patients with colon carcinoma than either numbers of lymph node metastases or tumor stage. More recently, Frey et al. investigated the prognostic significance of T Reg cells in CRC patients after their tumors had been stratified by mismatch repair (MMR) status. 93 They examined 1,197 MMR-proficient and 223 MMR-deficient CRCs. Fascinatingly, high FoxP3þ numbers (classified as more than 17 FoxP3þ cells per microarray tissue punch, approximately the same area as one 40Â field) in the MMR-proficient patients correlated with early T stage, tumor location (rectal) and better 5-year survival rate. In MMR-deficient CRCs, however, larger FoxP3þ populations were associated with an absence of lymph node involvement and absence of vascularization, along with a better 5-year survival rate. Finally, the investigators determined that an elevated FoxP3þ cell frequency served as an independent prognostic factor in MMR-proficient CRC and could predict enhanced survival in these patients.
Liver cancer
In 2007, Kobayashi et al. examined the infiltration of FoxP3þ T Regs and CD8þ T cells in the tumor stroma and nontumorous liver parenchyma of patients with liver cancer. 94 Their samples included 323 hepatic nodules (including precursor lesions), early hepatocellular carcinoma (HCC), and advanced HCC, in addition to 39 intrahepatic cholangiocarcinomas and 59 metastatic liver adenocarcinomas. The investigators found that T Reg numbers were significantly higher in HCC than in non-tumorous liver, and higher in primary HCC than in metastatic HCC. In both cases, HCC-infiltrating T Reg cell density was an independent prognostic factor. T Reg frequency was also increased in nontumorous liver (both with and without hepatitis) bearing primary tumors. Higher T Reg numbers within tumor tissue correlated with higher tumor grade and tended to correlate (p ¼ 0.064) with fewer infiltrating CD8þ T cells. The patient group with a high prevalence of T Regs (greater than 29% of CD4þ T cells) infiltrating HCC showed a significantly lower DFS and overall survival (OS) rate (27.3 and 45.1 months, respectively) than patients with fewer than 29% of CD4þ T cells identified as T Reg cells (36.2 and 60.3 months, respectively). Contrastingly, there was no significant difference in the OS or DFS between patients with low numbers of tumor-infiltrating CD8þ T and those with high numbers. Kobayashi et al. observed that during hepatocarcinogenesis, the prevalence of T Regs increased, while CD8þ T cell numbers decreased. This work supports the notion that primary hepatic cancers develop in liver that is immunosuppressed by large populations of T Reg cells. In the same year, Gao et al. published a manuscript detailing their investigation into the prognostic value of TILs in 302 HCC patients after tumor resection. 95 Interestingly, numbers of CD3þ, CD4þ and CD8þ TILs were not associated with patient survival. However, fewer intratumoral T Regs (<2.24 per 400Â field) in combination with more (>17.74 per 400Â field) activated CD8þ cytotoxic cells (CTLs, activation as defined by positive Granzyme B staining), served as an independent prognostic factor for both improved DFS and OS. Patients with high numbers of tumor-infiltrating T Regs and low numbers of CD8þ CTLs (fewer than 17.74 per 400Â field) had 5-year OS and DFS rates of 24.1 and 19.8%, respectively, whereas the group with low T Regs and high CD8þ CTLs had rates of 64.0 and 59.4%. Both T Regs alone and activated CTLs alone within the tumor served as independent predictors for OS. Patients with low numbers of intratumoral T Regs had longer OS (70 months) and DFS (69 months) than did those with high numbers of T Regs (higher than 2.24 per 400Â field; 51 and 34 months, respectively). Interestingly, the investigators found a correlation between high T Reg cell density and both absence of tumor encapsulation and presence of tumor vascular invasion, which suggests an association of T Reg cells with tumor invasiveness. If a CD8þ CTL-heavy balance of CTL and T Reg in the tumor microenvironment is indicative of better patient outcome, then therapy which increases CD8þ number and efficacy while simultaneously depleting T Reg cells would be ideal. In 2006, Cai et al. explored the potential of intratumoral DCs and T cells to serve as prognostic indicators in 123 patients who underwent surgical resection of hepatocellular carcinoma. 96 Although the investigators did not find a significant correlation between the number grade of infiltrating immune cells in HCC nodules or pericancerous tissues and DFS, they observed that an absolute number of DCs in HCC nodules of 25 or more per ten HPF did correlate with DFS. However, 28 or more DCs per ten HPF in pericancerous tissues had no correlation with survival. As might be expected, more DCs alone or with T lymphocytes (CD3þ, CD45ROþ or CD8þ), or more CD8þ T lymphocytes alone in HCC nodules strongly correlated to longer tumor-free survival time. It is important to consider this study because it explores numbers and locations of immune cells other than T Reg cells that likely interact with T Regs in the tumor microenvironment. In 2009, we published a study of B7-H1 and PD-1 expression in HCC patients in which we determined not only that B7-H1 expression on Kupffer cells (KC) was increased in tumor tissues compared with surrounding nontumor liver tissues, but also that this expression correlated with poor survival. 97 Additionally, numbers of PD-1þ CD8þ T cells were higher in tumor tissues than in non-tumor tissues, and B7-H1þ KCs and PD-1þ T cells colocalized in the HCC stroma. PD-1þ CD8þ T cells had decreased proliferative ability and effector function, but these attributes were rescued on PD-1/B7-H1 blockade. In summary, it is clear from the aforementioned studies that T Regs are not the only prognostic marker of survival in HCC patients. Zhang et al. recently published a study investigating the prognostic potential of Th17 cells in 178 patients with hepatocellular carcinoma. 98 The investigators found that Th17 cell numbers were higher in tumors of HCC patients than in non-tumor tissue, and that these Th17 displayed an effector memory phenotype. It was also determined that intratumoral frequency of IL-17-producing cells, which correlated proportionally with tumor microvessel density, could serve as an independent prognostic factor for OS and DFS. Other studies have documented a proangiogenic role for IL-17. 99, 100 In HCC, intratumoral density of Th17 cells is negatively associated with patient outcome.
Head and neck cancer
In 2006, a study from the laboratory of Eric Tartour investigated the prognostic value of various tumor-infiltrating CD4þ T-cell populations in 84 untreated patients with head and neck squamous cell carcinoma. 101 The investigators found that larger populations of tumor-infiltrating CD4þ CD69þ (activated) T cells (greater than 2.6 cells per field using a 40Â objective) correlated with both better local control of the tumor and longer patient survival. Interestingly, higher numbers of intratumoral regulatory Foxp3þ CD4þ T cells (more than 1.5 cells per 40Â field) were also positively associated with and served as an independent prognostic factor for better regional control of the tumor. CD4þ CD69þ T cells made up the only population within the tumor that significantly influenced OS: more infiltration correlated with better patient outcome. In head and neck cancer, T Reg cells may enact better local tumor control through suppression of inflammatory intermediates. 
Breast cancer

Lymphoma
Research from the lab of Miguel Piris in 2005 explored the relevance of T Reg and CTL (defined by TIA-1 and Granzyme B) populations in the reactive background of Hodgkin's lymphoma (HL) samples in the prognosis of 257 patients with classic HL (cHL). 102 Previous research reported by Oudejans et al. that increased numbers of CTLs were associated with poor patient outcome 103 was met with skepticism. 104 The 2005 report showed that a smaller population of FoxP3þ cells (lowest quartile of total patient numbers) combined with higher numbers of CTL (highest quartile) in the infiltrate served as an independent prognostic factor that negatively influenced event-free survival (EFS) and DFS in cHL patients. Alvaro et al. tested four cases in which patients relapsed and discovered that these samples tended to have more TIA-1þ cells and a lower proportion of FoxP3þ cells than at the time of diagnosis. The results of this investigation suggest that a combination of more CTLs with small numbers of FoxP3þ cells in the reactive background may predict a poor outcome in cHL patients. Three years later, Karube et al. analyzed the expression of FoxP3 in adult T-cell leukemia and lymphoma. 105 Interestingly, 60 (36%) of the 169 cases examined had FoxP3 expression in lymphoma cells. On closer examination, the investigators found that FoxP3þ and FoxP3À leukemia/lymphoma cases did not differ in clinical stage, age distribution, lactate dehydrogenase and calcium in serum or in overall survival. However, a larger proportion of FoxP3þ cases (8/34) suffered from severe infection; while in FoxP3À cases, only two of 62 patients did so. Karube et al. also demonstrated that FoxP3 expression in adult T-cell leukemia/lymphoma indicated certain morphological features (including chromosome abnormalities) and concluded that this T Reg marker is associated with patient immunosuppression.
Melanoma
In 2007, Miracco et al. analyzed 66 vertical growth phase primary cutaneous melanomas for correlation of T Reg cell presence with recurrence potential. 106 The investigators discovered that the percentage of T Regs within tumor parenchyma, at its periphery, and among TILs at the tumor-stroma boundary, was significantly higher in patients that experienced recurrence than in those that did not. Interestingly, many of the T Regs identified in these samples were found in close proximity to TAMs, the presence of which has been correlated to poor prognosis in patients with advanced melanoma. 107 Although the Miracco study did not analyze such parameters as distant metastases and patient survival, the preliminary data point to the possibility of using T Reg quantification as a prognostic indicator in melanoma.
Conclusions
Although regulatory T cells share functionality and mechanisms of suppression across cancers, it is important to recognize the individual (tumor-specific) nature of the T Reg component of any given tumor microenvironment. As we have reviewed above, T Regs play an important role in the development and maintenance of tumors and in the abrogation of the immune responses against them. In many cancers, elevated T Reg cell presence and number imply a worse prognosis for the patient in question. However, this is not always the case. As the studies of gastric, colorectal and anal cancer suggest, it seems that T Regs also have a different role. In these reports, increased T Reg populations within the tumor tissue seemed to be beneficial. It is interesting to note that all of these cancers are localized to the gastrointestinal tract, portions of which are sites of the most rapid cell turnover in the human body. It is possible that T Reg cells in this environment are more crucial for restraining inflammation (and thus preventing angiogenesis and other developments beneficial to tumor growth and survival) than for shutting off the host's response to the tumor. 108, 109 Chronic inflammation is often linked to cancer development in the gastrointestinal system. Further investigation into this phenomenon is warranted. In addition to tumor location, then, it is important to consider T Reg populations in the context of their upstream and downstream mediators, as well as alongside their cohorts in the tumor microenvironment. It is prudent to acknowledge the recently identified population of myeloid-derived suppressor cells (MDSC), the known functions of which thus far include inhibition of T cell activation, proliferation, migration and cytokine production through a variety of mechanisms.
110 As many studies have described, other T cell subsets and APCs (notably macrophages and dendritic cells) are significant in their relationships to intratumoral T Reg cells in the recruitment of T Regs into the tumor, influence of T Reg function within the tumor environment and in the molecules they (as target cells) upregulate in response to T Reg signaling. For example, IDO, a molecule induced in APC via CTLA-4 expression on T Reg , has been shown to diminish local CD8þ T cell infiltration and responses to allogeneic target cells in vitro and in vivo. 111 Interestingly, Sørensen et al. identified IDO-specific cytotoxic effector CD8þ T cells in the peripheral blood and tumor microenvironment of some cancer patients, 112 demonstrating that the immune system can mount responses against at least some of the mechanisms designed to suppress it. This affirms the importance of evaluating intratumoral T Reg presence in the context of other T cells, especially CD8þ T cells. Indeed, no single molecule or cell examined thus far within the tumor environment can serve as an absolutely independent indicator of patient survival. Therefore, it will be necessary to examine multiple tumor-associated cell populations in tandem with well-defined pathological, clinical and genetic parameters to more accurately predict patient outcome.
